Navigation Links
The cellular root of colorectal cancers?
Date:6/8/2011

June 8, 2011 Researchers at Children's Hospital Boston have found a marker called ABCB5 that both tags a small proportion of cells within colorectal cancers and fuels resistance in those cells to standard treatments. The results indicate that eliminating ABCB5-expressing cells is crucial for successful colorectal cancer treatment, while adding to the growing body of evidence for a theory of cancer growth called the cancer stem cell hypothesis.

An international team led by Brian J. Wilson, PhD, Tobias Schatton, PhD, and Markus Frank, MD, of the Transplantation Research Center at Children's Hospital Boston, and Natasha Frank, MD, of the VA Boston Healthcare System and Brigham and Women's Hospital, and colleagues at the University of Wurzburg in Germany reported the findings online in the journal Cancer Research on June 7, 2011.

An estimated 141,000 Americans will be diagnosed with colorectal cancer this year. While its mortality has been dropping over the last two decades thanks to screening and improved treatment options, colorectal cancer is still the second leading cause of cancer-related death in the United States.

Recognizing ABCB5's role as a marker of tumor recurrence in melanoma and liver cancer, and knowing from previous studies that the gene for ABCB5 is also active in colorectal cancer, the Franks' team studied the protein's expression in both normal and cancerous colorectal tissue specimens. They found that ABCB5 is found only rarely in healthy colorectal tissue, but is present at levels 23 times greater in cancerous tissue.

Underscoring its preferential expression on stem cells, ABCB5 was frequently accompanied on both healthy and cancerous cells by a second protein, CD133, which is thought to be a marker of both healthy intestinal stem cells and colorectal cancer stem cells. CD133 is also associated with aggressiveness in colorectal cancer.

To understand ABCB5's role in treatment resistance, the team examined biopsies gathered from colorectal cancer patients both before and after treatment with 5-fluorouracil (5-FU), a standard chemotherapeutic for this tumor. They found that the percentage of cells expressing ABCB5 increased more than five fold after treatment.

Using a mouse model of colorectal cancer, the researchers also found that cells expressing ABCB5 were markedly resistant to 5-FU. Knocking down ABCB5 expression both blocked the growth of these cells and restored their sensitivity to the drug, showing that ABCB5 is not only a marker of treatment resistance but actually drives it.

"With ABCB5, we have a molecule that is present at higher levels in colorectal cancers than in healthy cells, that marks the subset of cancer stem cells in human patients that will resist therapy, and that mediates that resistance at a functional level," said Markus Frank, a staff scientist Children's Department of Medicine and an assistant professor of pediatrics at Harvard Medical School. "It's a new mechanism of 5-FU resistance with very significant translational and therapeutic relevance," added Natasha Frank, a research associate at Children's Hospital Boston, an associate physician in the Division of Genetics at Brigham and Women's Hospital, and director of the Genetics Clinic at the VA Boston Healthcare System. "We think that these are the cells that need to be eliminated for successful treatment of colorectal cancer."

The cancer stem cell hypothesis holds that a fraction of the malignant cells in a tumor have characteristics associated with normal stem cells, namely the ability to self-renew and to give rise to other cell types. The hypothesis also holds that in order to successfully eliminate a tumor, the cancer stem cells must be eliminated as well; if they are not, they could serve as seeds for the tumor to regrow or spread.

"When the cancer stem cell concept was first posited, it was thought that the stem cell subset might coincide with the subset that remains after therapy and that metastasizes," Markus Frank said. "This subset has historically been a hidden target, because we have not been able to define and isolate it. But therapies capable of killing off those cells at the root of the cancer would be much more effective than those that miss this subset."


'/>"/>

Contact: Rob Graham
Rob.Graham@childrens.harvard.edu
617-919-3110
Children's Hospital Boston
Source:Eurekalert

Related medicine news :

1. The relationship between body mass index and age at hepatocellular carcinoma onset
2. Protein and microRNA block cellular transition vital to metastasis
3. A diagnostic marker in hepatocellular carcinoma
4. Springer to publish Cellular Oncology
5. New molecular imaging technologies for detecting cellular processes
6. BUSM investigates cellular mechanisms leading to immune response in airway epithelium
7. Positive psychological changes from meditation training linked to cellular health
8. c-Met may be a biomarker for metastatic hepatocellular carcinoma
9. A potential chemotherapeutic drug to treat hepatocellular carcinoma
10. Linc-ing a noncoding RNA to a central cellular pathway
11. Turning back the cellular clock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... conditions and Make-A-Wish grants the most heartfelt wishes of these children. The ... of medical treatment. President and CEO of Make-A-Wish Mississippi, Brent Wilson said, ...
(Date:5/5/2016)... ... ... Long Island’s fastest growing comprehensive eye care provider, North Shore Eye ... Valkenburg, MD as part of their ongoing effort to increase ophthalmic coverage in their ... of North Shore Eye Care. , “We are extremely proud to welcome ...
(Date:5/5/2016)... ... ... TIME for Kids and The ZAC Foundation – a national leader in drowning ... million children with important water safety messages before summer break begins. , ... in children one to 6 years of age. TIME for Kids and The ...
(Date:5/5/2016)... ... , ... In honor of National Nurses Week 2016, Aya Healthcare , ... to thank a nurse who's made a difference in their life. From Friday, May ... Cross of San Diego/Imperial Counties (up to $10,000) every time someone tells them via ...
(Date:5/5/2016)... ... ... Lung Institute will celebrate its three-year anniversary on May 14 by giving away a ... of May. To date, the Lung Institute has treated over 2,000 people at their five ... to the success of this treatment and to the patients who refuse to give up,” ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 2016 Research and ... Thalassaemia Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Competitive Landscape Highlights - 2016, provides comprehensive ... Thalassaemia market valuations and forecast, Thalassaemia products ...
(Date:5/4/2016)... May 4, 2016 According to ... entitled "Brain Computer Interface Market - Global Industry Analysis, Size, ... brain computer interface (BCI) market  is expected to reach ... is estimated to expand at a CAGR of 14.9 ... A BCI device provides collaboration between the ...
(Date:5/4/2016)... -- According to market research "Global Computed Tomography ... 2022 - Industry Insights by Slice Type (High, Mid and ... P&S Market Research, the global computed tomography market ... expected to grow at a CAGR of 5.0% during 2016-2022. ... expected to witness the faster growth, CAGR of 5.3%, during ...
Breaking Medicine Technology: